Genedrive plc (GDR) Ordinary 1.5p Shares
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
- Add to watchlist
- Create an alert
- This stock can be held in a
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
Share news, reports & tips
-
Director dealings: Genedrive chairman snaps up shares
15 August 2024 15:15
(Sharecast News) - Genedrive revealed on Thursday that chairman Ian Gilham had acquired 1.0m shares in the AIM-listed pharmacogenetic testing company.
-
Genedrive makes first commercial sales of CYP2C19-ID testing kit
12 August 2024 09:01
(Sharecast News) - Pharmacogenetic testing firm Genedrive said on Monday that it has made the first UK commercial sales of its CYP2C19-ID testing kit.
-
Genedrive test ordered by five Manchester area hospitals
24 May 2024 12:24
(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive announced on Friday that it has received initial orders for its Genedrive MT-RNR1 products from five additional UK hospitals in the...
-
Genedrive shares jump on NICE test recommendation
3 April 2024 13:54
(Sharecast News) - Genedrive shares were surging on Wednesday, after it received a significant endorsement from the UK's National Institute for Health and Care Excellence (NICE) regarding its...
-
Genedrive receives R&D tax credit, plans fundraise
15 March 2024 14:27
(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive announced the receipt of a research and development tax credit totalling £0.8m on Friday, taking its unaudited cash balances to...
-
Genedrive set to apply for NICE EVA funding
19 February 2024 10:56
(Sharecast News) - Genedrive shares rose on Monday, on the launch of the NICE early value assessment (EVA) evidence generation funding call, backed by the National Institute for Health and Care Research (NIHR).
-
Genedrive confirms £0.6m equity prepayment drawdown
2 January 2024 14:39
(Sharecast News) - Genedrive confirmed a planned £0.6m drawdown as part of its £5m equity prepayment facility on Tuesday, which it initially disclosed on 31 March 2023.
-
Genedrive gets first product orders from several countries
20 December 2023 13:57
(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive has received its first orders for Genedrive MT-RNR1 products from several countries, it announced on Wednesday, including France,...
-
Genedrive diagnostic test system gets UKCA registration
6 September 2023 13:55
(Sharecast News) - Point-of-care molecular diagnostics developer Genedrive announced on Wednesday that its Genedrive CYP2C19 System has received UKCA marking registration.
-
Genedrive draws down £0.3m under equity prepayment facility
5 July 2023 14:41
(Sharecast News) - Molecular diagnostics company Genedrive announced the latest drawdown of £0.3m under its £5m equity prepayment facility on Wednesday.
-
Genedrive secures multi-partner grant award
16 June 2023 10:49
(Sharecast News) - Molecular diagnostics specialist Genedrive announced its involvement in a multi-partner grant award called DEVOTE on Friday, supported by Innovate UK and the UK government's...
-
Genedrive jumps on draft NICE testing guidance
19 May 2023 16:03
(Sharecast News) - Point-of-care molecular diagnostics company Genedrive announced on Friday that the UK's National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending...
Company announcements Announcements
-
Director/PDMR Shareholding
15 August 2024 10:39
Genedrive
-
First UK commercial sales of the CYP2C19-ID Kit
12 August 2024 07:00
Genedrive
-
Directorate Change
6 August 2024 07:00
Genedrive
-
NICE recommends CYP2C19-ID Kit in final guidance
31 July 2024 07:00
Genedrive
-
Breakthrough Device Designation from the U.S. FDA
15 July 2024 07:00
Genedrive
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.